NCT01951261.

Methods	Study design: unknown centres; open‐label, parallel individual randomised controlled trial in Spain Duration: 24 weeks Setting: hospital
Participants	Population: 116 adults recruited from Spain Baseline characteristics: unknown Inclusion criteria: admitted to hospital with COPD exacerbation, w/o fever 48 hours, aerosol treatment every 6 hours, no other serious unstable disease, chest X‐ray without new disease, suitable environment for treatment with glucocorticoid intravenous < 40 mg twice daily Exclusion criteria: alcoholism, institutionalisation, not stable haemodynamics, ICU or on invasive mechanical ventilation during exacerbation, intravenous medicine, neoplasia or other chronic disease in terminal situation, inability to understand or participate in study
Interventions	Measurements taken at baseline and at 1, 4, and 24 weeks Treatment arms Telemonitoring of patient early discharge from hospital via phone and 3 nurse visits Usual care with early discharge from hospital and daily visits by hospital respiratory nurses and pulmonologists
Outcomes	Primary outcomes: time until first exacerbation Secondary outcomes: STAI, SATISFAD 10, medication adherence, telemonitoring compliance, number of home visits, CAT
Notes	Funding: unknown Other identifier:NCT01951261; TELEMEDCOPD